Sage Therapeutics to Present at Canaccord 38th Annual Growth Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug 1, 2018--Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the Company will present at the Canaccord 38th Annual Growth Conference on Wednesday, August 8, 2018 at 11:00 A.M. ET in Boston, MA.
A live webcast of the presentation can be accessed on the investor page of Sage’s website at investor.sagerx.com. A replay of the webcast will also be archived for up to 30 days on Sage’s website following the conference.
About Sage Therapeutics
Sage Therapeutics is a clinical-stage biopharmaceutical company committed to developing novel medicines to transform the lives of patients with life-altering CNS disorders. Sage has a portfolio of novel product candidates targeting critical CNS receptor systems, GABA A and NMDA. Sage’s lead program, a proprietary IV formulation of brexanolone (SAGE-547), has completed Phase 3 clinical development for postpartum depression and a New Drug Application is currently under review with the U.S. Food and Drug Administration. Sage is developing its next generation modulators, including SAGE-217 and SAGE-718, in various CNS disorders. For more information, please visit www.sagerx.com.
View source version on businesswire.com:https://www.businesswire.com/news/home/20180801005058/en/
CONTACT: Sage Therapeutics
Paul Cox, 617-299-8377
Maureen L. Suda, 585-355-1134
KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CLINICAL TRIALS PHARMACEUTICAL GENERAL HEALTH
SOURCE: Sage Therapeutics
Copyright Business Wire 2018.
PUB: 08/01/2018 06:30 AM/DISC: 08/01/2018 06:31 AM